AR071376A1 - Dihidropirazolonas sustituidas y su uso - Google Patents
Dihidropirazolonas sustituidas y su usoInfo
- Publication number
- AR071376A1 AR071376A1 ARP090101367A ARP090101367A AR071376A1 AR 071376 A1 AR071376 A1 AR 071376A1 AR P090101367 A ARP090101367 A AR P090101367A AR P090101367 A ARP090101367 A AR P090101367A AR 071376 A1 AR071376 A1 AR 071376A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- diseases
- radical
- solvates
- substituent
- Prior art date
Links
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 2
- 230000006806 disease prevention Effects 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract 1
- 208000014951 hematologic disease Diseases 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- ORTFAQDWJHRMNX-UHFFFAOYSA-N hydroxidooxidocarbon(.) Chemical group O[C]=O ORTFAQDWJHRMNX-UHFFFAOYSA-N 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 230000029663 wound healing Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Ophthalmology & Optometry (AREA)
- AIDS & HIV (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
Abstract
La presente solicitud se refiere a derivados de dihidropirazolona sustituidos, a procesos para su preparacion, a su uso para el tratamiento y/o la prevencion de enfermedades y a su uso para la preparacion de medicamentos para el tratamiento y/o a prevencion de enfermedades, en particular enfermedades cardiovasculares y hematologicas y enfermedades renales, y para potenciar la curacion de heridas. Reivindicacion 1: Compuesto de la formula (1) en la que X representa N o CH, R1 representa hidrogeno o ciano, R2 representa un radical heterociclilo saturado de 4 a 7 miembros que está unido a través de un átomo de nitrogeno, donde el radical heterociclilo puede estar sustituido con un sustituyente, donde el sustituyente está seleccionado del grupo que consiste en hidroxilo, hidroxicarbonilo, alquilo C1-3, alquil C1-3-amino y cicloalquilo C3-6, o donde el radical heterociclilo puede estar sustituido con 1 a 4 sustituyentes de fluor, o una de sus sales, solvatos o solvatos de las sales.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102008020113A DE102008020113A1 (de) | 2008-04-23 | 2008-04-23 | Substituierte Dihydropyrazolone und ihre Verwendung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR071376A1 true AR071376A1 (es) | 2010-06-16 |
Family
ID=40673347
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090101367A AR071376A1 (es) | 2008-04-23 | 2009-04-17 | Dihidropirazolonas sustituidas y su uso |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US8067407B2 (es) |
| EP (1) | EP2265602B1 (es) |
| JP (1) | JP5579165B2 (es) |
| KR (1) | KR20100135838A (es) |
| CN (1) | CN102015685B (es) |
| AR (1) | AR071376A1 (es) |
| AU (1) | AU2009240311B2 (es) |
| BR (1) | BRPI0911594A2 (es) |
| CA (1) | CA2722016C (es) |
| CL (1) | CL2009000906A1 (es) |
| CO (1) | CO6300844A2 (es) |
| CR (1) | CR11684A (es) |
| DE (1) | DE102008020113A1 (es) |
| DO (1) | DOP2010000282A (es) |
| EC (1) | ECSP10010494A (es) |
| ES (1) | ES2535458T3 (es) |
| HN (1) | HN2010001920A (es) |
| IL (1) | IL208136A0 (es) |
| MA (1) | MA32251B1 (es) |
| MX (1) | MX2010010324A (es) |
| NZ (1) | NZ588721A (es) |
| PE (1) | PE20091732A1 (es) |
| RU (1) | RU2509080C9 (es) |
| SV (1) | SV2010003674A (es) |
| TW (1) | TWI433846B (es) |
| UA (1) | UA105487C2 (es) |
| UY (1) | UY31765A (es) |
| WO (1) | WO2009129945A1 (es) |
| ZA (1) | ZA201006719B (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102008020113A1 (de) * | 2008-04-23 | 2009-10-29 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Dihydropyrazolone und ihre Verwendung |
| DE102005019712A1 (de) | 2005-04-28 | 2006-11-09 | Bayer Healthcare Ag | Dipyridyl-dihydropyrazolone und ihre Verwendung |
| DE102006050516A1 (de) | 2006-10-26 | 2008-04-30 | Bayer Healthcare Ag | Substituierte Dihydropyrazolone und ihre Verwendung |
| CN103052632B (zh) * | 2010-08-18 | 2014-03-19 | 山东亨利医药科技有限责任公司 | 二氢吡唑类化合物 |
| DE102010044131A1 (de) | 2010-11-18 | 2012-05-24 | Bayer Schering Pharma Aktiengesellschaft | Substituiertes Natrium-1H-pyrazol-5-olat |
| GB201102659D0 (en) | 2011-02-15 | 2011-03-30 | Isis Innovation | Assay |
| WO2012126275A1 (zh) * | 2011-03-18 | 2012-09-27 | 山东亨利医药科技有限责任公司 | 含有螺环的二氢吡唑类化合物 |
| GB201113101D0 (en) | 2011-07-28 | 2011-09-14 | Isis Innovation | Assay |
| AU2012318874A1 (en) * | 2011-10-06 | 2014-05-15 | Merck Sharp & Dohme Corp. | 1,3-substituted azetidine PDE10 inhibitors |
| WO2013057101A1 (de) * | 2011-10-17 | 2013-04-25 | Bayer Intellectual Property Gmbh | Substituierte oxadiazolylpyridinone und - pyridazinone als hif - hemmer |
| HK1208875A1 (en) * | 2012-01-12 | 2016-03-18 | 耶鲁大学 | Compounds & methods for the enhanced degradation of targeted proteins & other polypeptides by an e3 ubiquitin ligase |
| TW201400470A (zh) * | 2012-03-30 | 2014-01-01 | Daiichi Sankyo Co Ltd | ４－烷醇胺－３－吡唑哢衍生物 |
| DK2847183T3 (en) | 2012-05-08 | 2017-10-02 | Bayer Pharma AG | PROCEDURE FOR MAKING TRIAZOL COMPOUNDS |
| JOP20190080A1 (ar) * | 2016-10-14 | 2019-04-11 | Bayer Pharma AG | مركبات مشتقة من 6-(1h-بيرازول-1-يل) بيريميدين-4- أمين مستبدل واستخداماتها |
| EP3697776B1 (en) * | 2017-10-17 | 2023-04-19 | Palau Pharma, S.L.U. | Synthesis of 4-aminopyrimidine compounds |
| CN109694380B (zh) * | 2017-10-23 | 2022-09-27 | 中国医药研究开发中心有限公司 | 二氢吡唑啉酮类化合物及其制备方法和医药用途 |
| CN111825690B (zh) * | 2019-04-17 | 2022-09-27 | 中国医药研究开发中心有限公司 | 一种phd抑制剂的新晶型及其制备方法 |
| CN111825689B (zh) * | 2019-04-17 | 2023-05-05 | 中国医药研究开发中心有限公司 | 一种二氢吡唑啉酮类化合物的晶型及其制备方法 |
| CA3160364C (en) * | 2019-11-19 | 2024-11-05 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | COMPOUNDS AND USE FOR THE DIAGNOSIS, TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH ALPHA-SYNUCLEINE AGGREGATION |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GR63123B (en) | 1975-12-11 | 1979-09-11 | Lilly Co Eli | Preparation process of novel 1,4-diphenyl-3-pyrazolin-5-ones |
| US4075003A (en) | 1975-12-11 | 1978-02-21 | Eli Lilly And Company | Novel herbicidal method utilizing 1,4-diphenyl-3-pyrazolin-5-ones |
| PL103509B1 (pl) | 1976-09-20 | 1979-06-30 | Lilly Co Eli | Srodek chwastobojczy |
| US4663327A (en) | 1984-05-23 | 1987-05-05 | Bayer Aktiengesellschaft | 1-heteroaryl-4-aryl-pyrazolin-5-ones |
| DE3443308A1 (de) | 1984-11-28 | 1986-05-28 | Bayer Ag, 5090 Leverkusen | 1-heteroaryl-4-aryl-pyrazolin-5-one zur verwendung als arzneimittel |
| DE3527157A1 (de) | 1985-07-30 | 1987-02-12 | Bayer Ag | 1-heteroaryl-4-aryl-pyrazol-derivate |
| FR2725988B1 (fr) | 1994-10-24 | 1997-01-24 | Roussel Uclaf | Nouveaux derives de pyrazolones et pyrazoles acides, leur procede de preparation, les nouveaux intermediaires obtenus, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant |
| DE19909237A1 (de) | 1999-03-03 | 2000-09-07 | Merck Patent Gmbh | Pyrazol-3-on-derivate |
| US6878729B2 (en) | 2001-05-04 | 2005-04-12 | The Procter & Gamble Company | Medicinal uses of dihydropyrazoles |
| AU2002308748A1 (en) | 2001-05-16 | 2002-11-25 | Vertex Pharmaceuticals Incorporated | Heterocyclic substituted pyrazoles as inhibitors of src and other protein kinases |
| ES2295441T3 (es) | 2001-12-18 | 2008-04-16 | MERCK & CO., INC. | Moduladores de pirazol heteroaril sustituido de receptor 5 metabotropico de glutamato. |
| US20040176372A1 (en) | 2002-03-01 | 2004-09-09 | Pintex Pharmaceuticals, Inc. | Pin1-modulating compounds and methods of use thereof |
| US8124582B2 (en) | 2002-12-06 | 2012-02-28 | Fibrogen, Inc. | Treatment of diabetes |
| CA2522441A1 (en) * | 2003-03-27 | 2004-10-14 | Emory University | Hif-1 inhibitors |
| WO2004089303A2 (en) | 2003-04-03 | 2004-10-21 | Merck & Co., Inc. | Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5 |
| AU2004236690A1 (en) | 2003-05-01 | 2004-11-18 | Panacea Pharmaceuticals, Inc. | Methods of treating ischemic related conditions |
| CN1842332A (zh) * | 2003-06-30 | 2006-10-04 | Hif生物公司 | 化合物、组合物及方法 |
| AU2004275694B2 (en) | 2003-06-30 | 2008-03-06 | Bizbiotech Co., Ltd. | Compounds, compositions and methods |
| WO2006088491A2 (en) | 2004-06-29 | 2006-08-24 | Massachusetts Institute Of Technology | Methods and compositions related to the modulation of intercellular junctions |
| DE102008020113A1 (de) * | 2008-04-23 | 2009-10-29 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Dihydropyrazolone und ihre Verwendung |
| EP1861375A1 (en) | 2005-03-16 | 2007-12-05 | Aventis Pharmaceuticals Inc. | Dipyrazoles as central nervous system agents |
| DE102005019712A1 (de) | 2005-04-28 | 2006-11-09 | Bayer Healthcare Ag | Dipyridyl-dihydropyrazolone und ihre Verwendung |
| WO2007008541A2 (en) | 2005-07-08 | 2007-01-18 | Kalypsys, Inc. | Cellular cholesterol absorption modifiers |
| DE102006050515A1 (de) | 2006-10-26 | 2008-04-30 | Bayer Healthcare Ag | Substituierte Dipyridiyl-dihydropyrazolone und ihre Verwendung |
| DE102006050513A1 (de) | 2006-10-26 | 2008-04-30 | Bayer Healthcare Ag | Substitiuierte Dihydropyrazolone und ihre Verwendung |
| DE102006050516A1 (de) * | 2006-10-26 | 2008-04-30 | Bayer Healthcare Ag | Substituierte Dihydropyrazolone und ihre Verwendung |
| JP5237712B2 (ja) * | 2008-07-25 | 2013-07-17 | 公立大学法人 滋賀県立大学 | 静電紡糸装置 |
-
2008
- 2008-04-23 DE DE102008020113A patent/DE102008020113A1/de not_active Withdrawn
-
2009
- 2009-04-11 NZ NZ588721A patent/NZ588721A/xx not_active IP Right Cessation
- 2009-04-11 ES ES09733899.0T patent/ES2535458T3/es active Active
- 2009-04-11 CA CA2722016A patent/CA2722016C/en not_active Expired - Fee Related
- 2009-04-11 CN CN200980114292.9A patent/CN102015685B/zh not_active Expired - Fee Related
- 2009-04-11 UA UAA201013898A patent/UA105487C2/uk unknown
- 2009-04-11 BR BRPI0911594A patent/BRPI0911594A2/pt not_active IP Right Cessation
- 2009-04-11 MX MX2010010324A patent/MX2010010324A/es active IP Right Grant
- 2009-04-11 AU AU2009240311A patent/AU2009240311B2/en not_active Ceased
- 2009-04-11 EP EP09733899.0A patent/EP2265602B1/de active Active
- 2009-04-11 JP JP2011505403A patent/JP5579165B2/ja not_active Expired - Fee Related
- 2009-04-11 KR KR1020107023631A patent/KR20100135838A/ko not_active Ceased
- 2009-04-11 RU RU2010147404/04A patent/RU2509080C9/ru not_active IP Right Cessation
- 2009-04-11 WO PCT/EP2009/002693 patent/WO2009129945A1/de not_active Ceased
- 2009-04-14 UY UY0001031765A patent/UY31765A/es not_active Application Discontinuation
- 2009-04-14 PE PE2009000514A patent/PE20091732A1/es not_active Application Discontinuation
- 2009-04-15 CL CL2009000906A patent/CL2009000906A1/es unknown
- 2009-04-17 AR ARP090101367A patent/AR071376A1/es not_active Application Discontinuation
- 2009-04-22 US US12/427,749 patent/US8067407B2/en active Active
- 2009-04-22 TW TW098113265A patent/TWI433846B/zh not_active IP Right Cessation
-
2010
- 2010-09-14 IL IL208136A patent/IL208136A0/en unknown
- 2010-09-20 ZA ZA2010/06719A patent/ZA201006719B/en unknown
- 2010-09-21 CR CR11684A patent/CR11684A/es not_active Application Discontinuation
- 2010-09-21 EC EC2010010494A patent/ECSP10010494A/es unknown
- 2010-09-21 SV SV2010003674A patent/SV2010003674A/es not_active Application Discontinuation
- 2010-09-22 DO DO2010000282A patent/DOP2010000282A/es unknown
- 2010-09-22 CO CO10117239A patent/CO6300844A2/es active IP Right Grant
- 2010-09-22 HN HN2010001920A patent/HN2010001920A/es unknown
- 2010-10-20 MA MA33277A patent/MA32251B1/fr unknown
-
2011
- 2011-10-12 US US13/271,957 patent/US8580778B2/en active Active
-
2013
- 2013-10-07 US US14/047,652 patent/US20140038938A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR071376A1 (es) | Dihidropirazolonas sustituidas y su uso | |
| AR061548A1 (es) | 3-aminopirrolidino-4-lactamas sustituidas como inhibidoras de dipeptidilpeptidasa iv (dpp-iv), composiciones farmaceuticas que las comprenden y el uso de las mismas en el tratamiento de la diabetes ii. | |
| CO6260089A2 (es) | Activadores de guanilato ciclasas solubles | |
| ECSP11010880A (es) | Compuestos orgánicos | |
| CO6321276A2 (es) | Derivados de tiazol usados como inhibidores de pi3- cinasa | |
| UY31906A (es) | Derivados de n-cicloalquil-3-fenilnicotinamida que inhiben pgds, sus composiciones, su uso para el tratamiento por ejemplo de afecciones alérgicas y respiratorias. | |
| CU20170073A7 (es) | Compuestos de indazol sustituidos y compuestos intermediarios para la preparación de los mismos | |
| CO6341581A2 (es) | Derivados de heteroarilo como inhibidores de dgat1 | |
| AR077413A1 (es) | Derivados piridin-4-ilo | |
| AR070268A1 (es) | Compuesto de oxa-azaspiro, su uso para la fabricacion de un medicamento para la modulacion de receptores y5 de npy y composicion farmaceutica que lo comprende | |
| CU20100229A7 (es) | Compuestos triazina como inhibidores mtor y quinasa p13 | |
| AR074109A1 (es) | Pirrolidinas heterociclicas agonistas de receptores de la melanocortina, composiciones farmaceuticas que las contienen y uso de las mismas en el tratamiento de la obesidad, diabetes y disfuncion erectil. | |
| CO6351737A2 (es) | Amidofenoxiindazoles utiles como inhibidores de c-met | |
| AR070479A1 (es) | Derivado heterociclico fusionado y su uso | |
| AR074481A1 (es) | Derivados de tienopiridina como inhibidores de quinasa | |
| AR077080A1 (es) | Compuestos de 2,3-dihidro-1h-indeno | |
| UY31134A1 (es) | Derivados de piperidina/piperazina (i) | |
| UY32004A (es) | Derivados de carbamatos de alquiltiazoles, su preparación y su aplicación en terapéutica | |
| AR078142A1 (es) | Compuestos inhibidores heteroarilicos biciclicos de pde4, las composiciones farmaceuticas que los contienen y el uso de los mismos para la preparacion de medicamentos. | |
| EA201791671A1 (ru) | 4-замещенные соединения бензоксаборола и их применение | |
| CL2022001357A1 (es) | Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso | |
| AR104331A1 (es) | Derivados de tetrazol | |
| CR20110360A (es) | Derivados de 2-piridin-2-il-pirazol-3-(2h)-ona, su preparacion y su aplicacion en terapeutica | |
| PE20141391A1 (es) | Combinacion que comprende un compuesto con actividad antiviral y un agente terapeutico | |
| AR072880A1 (es) | Derivados nitrogenados de la pancratistatina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal | ||
| FB | Suspension of granting procedure |